Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Article Commentary
Authors: Høilund-Carlsen, Poul F.a; b; * | Alavi, Abassc
Affiliations: [a] Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark | [b] Department of Clinical Research, University of Southern Denmark, Odense, Denmark | [c] Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Correspondence: [*] Correspondence to: Poul F. Høilund-Carlsen, MD, DMSc, Prof (Hon), Professor of Clinical Physiology, Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark. Tel.: +45 25215445; E-mail: [email protected]; ORCID ID 0000-0001-7420-2367
Abstract: According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques—a hallmark finding in patients with Alzheimer’s disease—and this will result in a reduction in clinical decline. The authors of this article are not convinced that amyloid deposits are a hallmark of Alzheimer’s disease and are of the opinion that the apparent reduction in amyloid accumulation following aducanumab treatment is likely instead a result of continued and advanced cerebral cell death and, thus, not a sign of improvement but of an even more advanced disease.
Keywords: Aducanumab, aduhelm, Alzheimer’s disease, amyloid PET, dementia
DOI: 10.3233/JAD-215275
Journal: Journal of Alzheimer's Disease, vol. 84, no. 4, pp. 1457-1460, 2021
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]